Clinical trial NCT03028909: Dose Ranging Study to Evaluate the Efficacy and Safety of MEDI8852 in Adults Who Are Hospitalized With Type A Influenza.
Official title: A Phase 2b, Randomized, Double-blind, Single-dose, Active-controlled, Dose Ranging Study to Evaluate the Efficacy and Safety of MEDI8852 in Adults Who Are Hospitalized With Influenza Caused by Type A Strains
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE2
Conditions: Influenza - Type A Strains
Keywords: Influenza A
MEDI8852
Lead sponsor: MedImmune LLC
Sponsor class: INDUSTRY
First posted: 2017-01-23
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purposes of this study are to determine if MEDI8852 administered with standard of care (oseltamivir) will reduce the time to normalization of respiratory function for adults who are hospitalized with influenza caused by Type A strains and to determine if MEDI8852 has an acceptable safety profile in adults who are hospitalized with influenza caused by Type A strains.

Detailed description: The MEDI8852 phase 2b study will evaluate the efficacy and safety of a single intravenous (IV) dose of MEDI8852 or placebo administered in conjunction with oseltamivir in adult subjects who are hospitalized with influenza caused by Type A strains. Approximately 450 subjects will be enrolled at study centers in North America, Europe, and other regions.

Eligibility criteria: Inclusion Criteria:

Age 18 years or older at the time of screening. Written informed consent and any locally required authorization (eg, Health Insurance Portability and Accountability Act \[HIPAA\] in the United States, Data Privacy Directive in Europe) obtained from the subject/legal representative prior to performing any protocol related procedures, including screening evaluations.

Females of childbearing potential who are sexually active with a nonsterilized male partner must have evidence of not being pregnant upon enrollment and have a negative pregnancy test prior to administration of investigational product. Females of childbearing potential are defined as those who are not surgically sterile (ie, bilateral tubal ligation, bilateral oophorectomy, or complete hysterectomy), premenarchal, or postmenopausal (defined as 12 months with no menses without an alternative medical cause). Hospitalized ≤ 72 hours prior to receipt of a positive diagnostic test for influenza A; confirmed with positive rapid antigen test (supplied or approved by the sponsor), or confirmed with culture, polymerase chain reaction, or antigen testing at the study site. Onset of influenza symptoms ≤ 144 hours (≤ 6 days) prior to randomization. Receiving supplemental oxygen. Expected to participate in the study through Day 60.

Exclusion Criteria:

* Any condition that, in the opinion of the investigator, would interfere with evaluation of study drugs or interpretation of subject safety or study results.
* Concurrent enrollment in another clinical study involving an investigational treatment. -Hospitalized \> 72 hours (\> 3 days) prior to receipt of a positive diagnostic test for influenza A.
* Receipt of \> 72 hours or \> 6 doses of treatment with a neuraminidase (NA) inhibitor. -Receipt of any investigational antiviral medications within 30 days prior to study drug dosing.
* Previous receipt of an influenza mAb within past 100 days.
* Pregnant or nursing female.
* History of allergic disease or reactions likely to be exacerbated by any components of the study drugs (MEDI8852 or oseltamivir).
* Diagnosis of influenza B infection within 14 days prior to randomization.
* Employees of the sponsor, clinical study site, or any other individuals involved with the conduct of the study, or immediate family members of such individuals.

Primary outcomes:
measure: Evaluation of efficacy as defined as time to normalization of respiratory function.
timeFrame: Through Day 14
measure: The occurence of Adverse Events
timeFrame: Through Day 28
measure: The occurence of Serious Adverse Events
timeFrame: Through Study Day 60
measure: The occurence of Adverse Events of Special Interest (AESIs)
timeFrame: Through Day 60
Secondary outcomes:
measure: Assessment of the effect of MEDI8852 in reducing severity of clinical status.
timeFrame: Through Day 7
measure: Evaluation of time to hospital discharge.
timeFrame: Through Day 60
measure: Quantitation of influenza viral shedding by qRT-PCR.
timeFrame: Through Day 60
measure: Evaluation of serum concentrations and PK of MEDI8852.
timeFrame: Through Day 60
measure: Evaluation of serum ADA responses in serum through Day 60.
timeFrame: Through Day 60
measure: Evaluation of time to ICU discharge.
timeFrame: Through Day 60
measure: Evaluation of the effect of MEDI8852 in reducing time to clinical resolution of individual vital sign abnormalities.
timeFrame: Through Day 14
measure: Evaluation of Change in NEWS from baseline through Day 14.
timeFrame: Through Day 14
measure: Evaluation of the effect of MEDI8852 in reducing the duration of mechanical ventilation.
timeFrame: Through Day 60
measure: Evaluation of the effect of MEDI8852 in reducing the rates of ICU admission from the general ward.
timeFrame: Through Day 60
measure: Evaluation to determine the effect of MEDI8852 on all-cause mortality
timeFrame: Through Day 60
measure: Evaluation of the effect of MEDI8852 on all-cause re-admission rates during the study.
timeFrame: Through Day 60
Other outcomes:
Locations:
Study officials:
References: